Patent Filing

Element Biosciences unveils VITARI, a high-throughput benchtop sequencer promising a $100 whole genome, challenging market giants and democratizing genomics.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

Aucta Pharma launches two rare disease drugs, PYQUVI and ZELVYSIA, betting on a 'branded-generic' model to navigate highly competitive markets.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

Shareholders to vote on a US$3.65 per share all-cash deal, a significant premium that will take the growing respiratory care provider private.

X-BATT's new patent aims to reduce fire risk in lithium-ion batteries, boosting consumer trust and unlocking new markets for the technology.

A nationwide study, with NFL legend Steve Gleason as Participant #1, seeks to uncover why high-performance groups face a disproportionate risk of ALS.

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.

Quetzal Therapeutics’ oral capsule for a rare leukemia could replace grueling IVs. The FDA's Fast Track status signals a major shift for patients and investors.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

A Texas court dismisses all claims against entrepreneur Tahir Javed, revealing a deeper story of political rivalry and alleged online misinformation.

A new FDA-cleared test detects RSV, Flu A/B, and COVID from a single swab, offering a powerful diagnostic tool for families, especially for infants.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

As founder Patrick Gruber steps back, incoming CEO Paul Bloom is set to commercialize Gevo's green tech, focusing on profitability and its ambitious SAF goals.

Canadian giant Aurora Cannabis gains exclusive EU rights for two key strains, signaling a new era of genetic ownership in Europe's booming medical market.

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Kent Imaging denies patent infringement claims from rival MolecuLight over its new SnapshotGLO device, sparking a high-stakes legal battle at the ITC.